There is extensive evidence that APOE plays a central role in modulating AD pathogenesis by varying effects on net oligomerization/aggregation of Aβ and Tau, as well as various inflammatory and recovery pathways, and response in clinical trials. The gene discussed is MAPT; the disease is Alzheimer disease.